Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.
Cannabidiol is a non-psychotomimetic compound from Cannabis sativa. It is proposed as a possible antipsychotic drug, since it can prevent some psychotomimetic-like effects of Delta9-tetrahydrocannabinol or apomorphine. Therefore, the aim of this work was to test the hypothesis that cannabidiol would inhibit the hyperlocomotion induced by two psychotomimetic drugs, D-amphetamine or ketamine. Male Swiss mice received i.p. injections of haloperidol (0.15-0.6 mg/kg), clozapine (1.25-5 mg/kg) or cannabidiol (15-60 mg/kg) followed by D-amphetamine (5 mg/kg) or ketamine (60 mg/kg). Thirty minutes after the first injection, the distance moved in circular arena was measured during 10 min. In another group of experiments, catalepsy was measured 30 min after haloperidol, clozapine or cannabidiol injections. Cannabidiol, like clozapine but unlike haloperidol, inhibited hyperlocomotion without inducing catalepsy. Moreover, cannabidiol itself, unlike haloperidol and clozapine, did not decrease locomotion. In conclusion, cannabidiol exhibits an antipsychotic-like profile without inducing extrapyramidal-like effects.[1]References
- Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Moreira, F.A., Guimarães, F.S. Eur. J. Pharmacol. (2005) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
